Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. More Details
Solid track record with high growth potential.
Share Price & News
How has Neurocrine Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NBIX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NBIX underperformed the US Biotechs industry which returned 31.5% over the past year.
Return vs Market: NBIX underperformed the US Market which returned 14.2% over the past year.
Price Volatility Vs. Market
How volatile is Neurocrine Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StCould The Market Be Wrong About Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Its Attractive Financial Prospects?
4 weeks ago | Simply Wall StHere's Why I Think Neurocrine Biosciences (NASDAQ:NBIX) Is An Interesting Stock
1 month ago | Simply Wall StHere's What We Learned About The CEO Pay At Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NBIX ($101.87) is trading below our estimate of fair value ($245.65)
Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NBIX is poor value based on its PE Ratio (46x) compared to the US Biotechs industry average (22.2x).
PE vs Market: NBIX is poor value based on its PE Ratio (46x) compared to the US market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: NBIX is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: NBIX is overvalued based on its PB Ratio (11.4x) compared to the US Biotechs industry average (3.4x).
How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NBIX's forecast earnings growth (35.9% per year) is above the savings rate (2.2%).
Earnings vs Market: NBIX's earnings (35.9% per year) are forecast to grow faster than the US market (23.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NBIX's revenue (18.5% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: NBIX's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (31.7%)
How has Neurocrine Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NBIX has a large one-off loss of $123.1M impacting its June 30 2020 financial results.
Growing Profit Margin: NBIX's current net profit margins (20.4%) are higher than last year (3%).
Past Earnings Growth Analysis
Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 49.5% per year.
Accelerating Growth: NBIX's earnings growth over the past year (1033.1%) exceeds its 5-year average (49.5% per year).
Earnings vs Industry: NBIX earnings growth over the past year (1033.1%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: NBIX's Return on Equity (24.6%) is considered high.
How is Neurocrine Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NBIX's short term assets ($1.1B) exceed its short term liabilities ($573.0M).
Long Term Liabilities: NBIX's short term assets ($1.1B) exceed its long term liabilities ($111.4M).
Debt to Equity History and Analysis
Debt Level: NBIX's debt to equity ratio (50.5%) is considered high.
Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NBIX's debt is well covered by operating cash flow (85.2%).
Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (24.8x coverage).
What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Gorman (62 yo)
Dr. Kevin C. Gorman, Ph.D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman served ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD9.45M) is about average for companies of similar size in the US market ($USD7.31M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
|CEO & Director||12.67yrs||US$9.45m||0.47% |
|Chief Financial Officer||2.83yrs||US$5.82m||0.0086% |
|Chief Development Officer||13.75yrs||US$4.78m||0.16% |
|Chief Commercial Officer||5.33yrs||US$5.79m||0.016% |
|Chief Medical Officer||2.67yrs||US$4.90m||0.012% |
|Chief Research Officer||13.67yrs||US$3.33m||0.085% |
|Head of Investor Relations||no data||no data||no data|
|Chief Legal Officer & Corporate Secretary||5.92yrs||no data||0.030% |
|Chief Business Development and Strategy Officer||9.67yrs||US$4.57m||0.10% |
|Chief Human Resources Officer||3yrs||no data||0.0093% |
|Chief Regulatory Officer||6yrs||no data||0.029% |
|Chief Corporate Affairs Officer||1yr||no data||no data|
Experienced Management: NBIX's management team is seasoned and experienced (5.9 years average tenure).
|CEO & Director||12.67yrs||US$9.45m||0.47% |
|Independent Director||22.42yrs||US$531.60k||0.032% |
|Independent Director||21.42yrs||US$534.60k||0.032% |
|Independent Chairman of the Board||9.33yrs||US$671.98k||0.027% |
|Independent Director||27.58yrs||US$507.10k||0.24% |
|Independent Director||4.92yrs||US$528.60k||0% |
|Independent Director||0.58yr||no data||0% |
|Independent Director||1yr||US$804.35k||0% |
Experienced Board: NBIX's board of directors are seasoned and experienced ( 11 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neurocrine Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Neurocrine Biosciences, Inc.
- Ticker: NBIX
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.500b
- Shares outstanding: 93.25m
- Website: https://www.neurocrine.com
Number of Employees
- Neurocrine Biosciences, Inc.
- 12780 El Camino Real
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NBIX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1996|
|NB3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1996|
|0K6R||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1996|
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/18 06:04|
|End of Day Share Price||2020/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.